Your browser doesn't support javascript.
loading
Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs.
O'Byrne, Sorcha; Elliott, Natalina; Rice, Siobhan; Buck, Gemma; Fordham, Nicholas; Garnett, Catherine; Godfrey, Laura; Crump, Nicholas T; Wright, Gary; Inglott, Sarah; Hua, Peng; Psaila, Bethan; Povinelli, Benjamin; Knapp, David J H F; Agraz-Doblas, Antonio; Bueno, Clara; Varela, Ignacio; Bennett, Phillip; Koohy, Hashem; Watt, Suzanne M; Karadimitris, Anastasios; Mead, Adam J; Ancliff, Phillip; Vyas, Paresh; Menendez, Pablo; Milne, Thomas A; Roberts, Irene; Roy, Anindita.
Afiliação
  • O'Byrne S; Department of Paediatrics and.
  • Elliott N; Department of Paediatrics and.
  • Rice S; Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Buck G; Department of Paediatrics and.
  • Fordham N; Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Garnett C; Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Godfrey L; Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Crump NT; Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Wright G; Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Inglott S; Department of Haematology, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom.
  • Hua P; Department of Haematology, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom.
  • Psaila B; Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Povinelli B; Stem Cell Research, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Knapp DJHF; Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Agraz-Doblas A; Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Bueno C; Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Varela I; Instituto de Biomedicina y Biotecnología de Cantabria, Universidad de Cantabria-CSIC, Santander, Spain.
  • Bennett P; Josep Carreras Leukemia Research Institute-Campus Clinic, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
  • Koohy H; Josep Carreras Leukemia Research Institute-Campus Clinic, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
  • Watt SM; Instituto de Biomedicina y Biotecnología de Cantabria, Universidad de Cantabria-CSIC, Santander, Spain.
  • Karadimitris A; Institute of Reproductive and Developmental Biology, Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom.
  • Mead AJ; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
  • Ancliff P; Stem Cell Research, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Vyas P; Centre for Haematology, Department of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom.
  • Menendez P; Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Milne TA; Haematology Theme, Oxford Biomedical Research Centre, Oxford University Hospitals, Oxford, United Kingdom.
  • Roberts I; Department of Haematology, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom.
  • Roy A; Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
Blood ; 134(13): 1059-1071, 2019 09 26.
Article em En | MEDLINE | ID: mdl-31383639
ABSTRACT
Human lymphopoiesis is a dynamic lifelong process that starts in utero 6 weeks postconception. Although fetal B-lymphopoiesis remains poorly defined, it is key to understanding leukemia initiation in early life. Here, we provide a comprehensive analysis of the human fetal B-cell developmental hierarchy. We report the presence in fetal tissues of 2 distinct CD19+ B-progenitors, an adult-type CD10+ve ProB-progenitor and a new CD10-ve PreProB-progenitor, and describe their molecular and functional characteristics. PreProB-progenitors and ProB-progenitors appear early in the first trimester in embryonic liver, followed by a sustained second wave of B-progenitor development in fetal bone marrow (BM), where together they form >40% of the total hematopoietic stem cell/progenitor pool. Almost one-third of fetal B-progenitors are CD10-ve PreProB-progenitors, whereas, by contrast, PreProB-progenitors are almost undetectable (0.53% ± 0.24%) in adult BM. Single-cell transcriptomics and functional assays place fetal PreProB-progenitors upstream of ProB-progenitors, identifying them as the first B-lymphoid-restricted progenitor in human fetal life. Although fetal BM PreProB-progenitors and ProB-progenitors both give rise solely to B-lineage cells, they are transcriptionally distinct. As with their fetal counterparts, adult BM PreProB-progenitors give rise only to B-lineage cells in vitro and express the expected B-lineage gene expression program. However, fetal PreProB-progenitors display a distinct, ontogeny-related gene expression pattern that is not seen in adult PreProB-progenitors, and they share transcriptomic signatures with CD10-ve B-progenitor infant acute lymphoblastic leukemia blast cells. These data identify PreProB-progenitors as the earliest B-lymphoid-restricted progenitor in human fetal life and suggest that this fetal-restricted committed B-progenitor might provide a permissive cellular context for prenatal B-progenitor leukemia initiation.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neprilisina / Linfopoese / Células Precursoras de Linfócitos B / Feto Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Blood Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neprilisina / Linfopoese / Células Precursoras de Linfócitos B / Feto Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Blood Ano de publicação: 2019 Tipo de documento: Article
...